MetaCap

Fate Therapeutics (FATE) vs Molecular Partners (MOLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Molecular Partners (MOLN) over the past year, losing 10.8% versus a loss of 37.5%. Over five years, MOLN leads with a -77.9% price change compared with -98.3% for FATE. Fate Therapeutics is the larger company by market cap ($111.8 million vs $96.8 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FATE-10.78%MOLN-37.50%
+214%+82%-49%
Nov 21, 20251 yearNov 20, 2026
FATE-98.36%MOLN-75.84%
+220%+53%-114%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FATE versus MOLN key metrics
MetricFATEMOLN
Share price$0.919$2.53
Market cap$111.82M$96.80M
1-day change-9.01%-5.25%
YTD return-6.22%-42.07%
1-year return-10.78%-37.50%
5-year return-98.25%-77.87%
EPS (TTM)$-1.03$-1.68
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.65M—
Revenue growth (YoY)-51.24%—
Net income (latest FY)$-136.31M—
Operating margin-2222.45%—
Net margin-2051.08%—
52-week high$3.23$5.36
52-week low$0.90$2.52
Distance from 52-week high-71.55%-52.89%
Analyst consensusbuystrong_buy
Avg. price target upside+522.42%+295.64%
Average volume1.53M1.63K
Shares outstanding121.67M38.34M
Employees161134
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed MOLN by 26.7 percentage points over the past year.

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

About Molecular Partners

MOLN stock →

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

FATE vs MOLN FAQ

Which is bigger, Fate Therapeutics or Molecular Partners?

Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $96.80M for Molecular Partners (MOLN).

Which stock has performed better over the past year, FATE or MOLN?

FATE returned -10.78% over the past 12 months, compared with -37.50% for MOLN (price return, excluding dividends). Past performance does not predict future results.

Are Fate Therapeutics and Molecular Partners in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons